Quarterly Result16 May 2025, 02:00 pm
Jubilant Pharmova: On Track Towards Realizing Vision 2030 with Sustained Growth and EBITDA Margin Expansion
AI Summary
Jubilant Pharmova Ltd. has reported its Q4 and FY25 results, showing sustained growth momentum, EBITDA margin expansion, and Net Debt/EBITDA reduction. The company saw strong industry tailwinds in its CDMO Sterile Injectable business in the post-tariff world. Highlights include a 8% YoY revenue growth, 24% EBITDA growth, and a 112% increase in normalised PAT. The company also made significant strides in its Radiopharma, Allergy Immunotherapy, and CRDMO businesses, and started distributing Pylarify®, an industry-leading prostate cancer diagnostic imaging agent.
Key Highlights
- Revenue of Rs. 7,235 Cr. in FY25, growth of 8% over last year
- EBITDA grew by 24% to Rs. 1,230 Cr.
- EBITDA margins for the year expanded by 220 basis points
- Normalised PAT grew by 112% to Rs. 415 Cr.
- Net Debt / EBITDA reduced from 2.5x in Mar’24 to 1.1x in Mar’25